Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA, FTC shoot down GermBullet claims; Emu products cited for disease claims; Novartis cough/cold recall in Canada; Super Power spiked with sildenafil; more Regulatory News In Brief.

You may also be interested in...



OTC Cough/Cold Resumes Line Extension, Launch Activity

Firms are returning to line extension activity for iconic brands such Alka-Seltzer, Robitussin, Triaminic and Vicks, some with OTC monograph ingredients added to provide new indications. Market researchers project category growth through 2014 and discuss factors affecting cough/cold product sales.

OTC Cough/Cold Resumes Line Extension, Launch Activity

Firms are returning to line extension activity for iconic brands such Alka-Seltzer, Robitussin, Triaminic and Vicks, some with OTC monograph ingredients added to provide new indications. Market researchers project category growth through 2014 and discuss factors affecting cough/cold product sales.

Flu Therapy “Scammers” Prompt FDA, FTC Warnings

Recent FDA warning letters include one to Oasis Consumer Healthcare regarding marketing and labeling for Halo Oral Antiseptic Spray. The agency also teamed with FTC to warn three online health stores for making flu claims for supplement products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106214

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel